Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor.
Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor.
复制标题
DOI：
10.1007/s10120-005-0315-x
复制
发表时间：
2005-01-01
期刊：
影响因子：
--
通讯作者：
Aoki, Tatsuya
中科院分区：
文献类型：
--
作者：
Ashizawa, Tatsuto;Okada, Ryosuke;Aoki, Tatsuya
背景：越来越清楚的是，各种细胞因子与癌细胞的扩散有关。本研究的目的是比较胃癌患者白细胞介素(IL)-6的水平，以阐明IL-6在预测肿瘤扩散中的作用。方法：在60例患者中，我们评估血清IL-6 （pg/ml）与分期、组织学表现、肝转移及相关因子（肝细胞生长因子[HGF]、il -1 β、肿瘤坏死因子[TNF]- α、转化生长因子[TGF]- β 1）的相关性。我们还探讨了IL-6水平对晚期胃癌和淋巴结转移的诊断意义，以及IL-6升高与预后的关系。最后，我们检测了IL-6在肿瘤组织中的表达。结果：血清IL-6与肿瘤分期、浸润深度（pT）、淋巴浸润（ly）、静脉浸润(v)*、淋巴结转移（pN）、肝转移（cH）、HGF均有显著相关性（P < 0.01; *P < 0.05）。IL-6水平对晚期胃癌及淋巴结转移的诊断意义：IL-6临界值为1.97 pg/ml时，敏感性分别为81.8%和87.5%；特异性分别为66.7%和58.3%；准确率分别为77.1%和72.9%。IL-6≥1.97 pg/ml患者的1年和3年累积生存率（分别为69.0%和43.4%）显著低于IL-6≥1.97 pg/ml患者（分别为94.4%和87.2%,P < 0.05）。免疫组化染色显示癌细胞细胞质中IL-6阳性。结论：我们推测IL-6参与了肿瘤侵袭、淋巴结和/或肝脏转移。我们的结果表明，IL-6可以作为生存的预后因素。
BACKGROUND: It is becoming clear that various cytokines are associated with the spread of cancer cells. The purpose of this study was to compare interleukin (IL)-6 levels in patients with gastric cancer to elucidate the role of IL-6 in predicting the spread of tumors.METHODS: In 60 patients, we assessed the correlation of serum IL-6 (pg/ml) with stage, histological findings, hepatic metastasis, and related factors (hepatocyte growth factor [HGF], IL-1beta, tumor necrosis factor [TNF]-alpha, and transforming growth factor [TGF]-beta1). We also investigated the diagnostic significance of the IL-6 level for advanced gastric cancer and lymph node metastasis, as well as the association between IL-6 elevation and outcome. Finally, we examined the expression of IL-6 in tumor tissue.RESULTS: Significant relationships were seen between serum IL-6 and stage, depth of tumor invasion (pT), lymphatic invasion (ly), venons invasion (v)*, lymph node metastasis (pN), hepatic metastasis (cH), and HGF (P < 0.01; *P < 0.05). With regard to the diagnostic significance of the IL-6 level for advanced gastric cancer and lymph node metastasis, when the cutoff value of IL-6 was set at 1.97 pg/ml, the sensitivity was 81.8% and 87.5%; specificity was 66.7% and 58.3%; and accuracy was 77.1% and 72.9%, respectively. The 1- and 3-year cumulative survival rates for patients with an IL-6 value of more than 1.97 pg/ml (69.0% and 43.4%, respectively) were significantly lower than those for patients with an IL-6 value of 1.97 pg/ml or less (94.4% and 87.2%, respectively; P < 0.05). Immunohistochemical staining was positive for IL-6 in the cytoplasm of cancer cells.CONCLUSION: We suspect that IL-6 is involved in cancer invasion and lymph node and/or hepatic metastasis. Our results indicate that IL-6 could be used as a prognostic factor for survival.